CRISPR Therapeutics (NasdaqGM:CRSP) recently announced the departure of Chief Operating Officer Julianne Bruno, reflecting a notable leadership change that could influence its operational direction.

The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.

Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases ...

Crispr Therapeutics said Chief Operating Officer Julianne Bruno would depart the company to pursue other opportunities, effective April 11. Bruno joined the gene-editing company in 2019 and stepped ...

Crispr Therapeutics (CRSP) announced that its COO, Julianne Bruno, will be stepping down from the company to pursue external opportunities, ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

A Peninsula biotech company raised $68 million from investors — including a venture philanthropy fund started by Lululemon ...

The startup is using CRISPR tools to stop errant expression of a gene linked to facioscapulohumeral muscular dystrophy, a disorder on the radars of several drugmakers.

Avantax Advisory Services Inc. acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and ...

Expanding CRISPR's Potential Since its discovery, CRISPR (“Clustered Regularly Interspaced Short Palindromic Repeats”), which ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...